“I am an advocate for psychedelics. I can’t help it,” explains 57-year-old Jacqueline Lopez, “I mean, it wasn’t that long ago that I thought to myself, ‘What are you thinking, Jackie? These are Schedule I drugs. You can’t just go around talking about them.’ But the science behind it is superb and I had seen…
This examination of a large international sample of adults highlights the prominence of therapeutic and wellness motivations for microdosing psychedelic drugs and identified lower levels of anxiety and depression among microdosers relative to controls. Comparisons of psilocybin to LSD microdosers indicated no differences on measures of Depression, Anxiety and Stress from the DASS-21 (all values for F (1, 827) < 1.0, p > 0.50). The inclusion of…
…nearly every day, another psychedelics company announces its work in securing patents for the intellectual property represented by the product they developed… a quick search of the USPTO site shows that there are currently hundreds of patents related to LSD and Psilocybin products and formulations. Psilocybin (U.S. Patent No. 3,183,172, “Obtaining Psilocybin and Psilocin from…
[Case reports]: LSD… was better for more puzzle-like creativity – for solo pondering over a question or engaging in a writing task…. …[psilocybin] reminded me of what psychologists call the fundamental attribution error, or the tendency to attribute someone else’s poor performance to inherent defects in their personality but blame our own slip-ups on someone else.…
The story of CB, a 49-year-old woman, and her roommate, who witnessed the event. CB had contracted Lyme disease in her early 20s, and by the LSD event, she experienced significant pain in her feet and ankles, routinely taking morphine for a decade… CB snorted… pure LSD – 550 times the normal recreational dosage of…
“The findings suggest that lifetime classic psychedelic use is associated with lower odds of having had heart disease or diabetes in the past year,” lead study author and Oxford sociologist Otto Simonsson, [said]. A team of scientists identified the unexpected trend after poring over ten years’ worth of data from the National Survey on Drug…
Brain-derived neurotrophic factor (BDNF) regulates neuronal development and survival and triggers adaptive neuroplasticity… animal studies have reported that acute and chronic administration of various psychedelic compounds, including LSD, psilocybin, DMT, and other ayahuasca-derived alkaloids, can increase BDNF production and neurogenesis (the formation of new neurons). Importantly, threats to our well-being such as stress, ageing and…
Perhaps the most intriguing finding in the study is the observation that the analgesic effect seen in the 20-µg LSD group is comparable to what prior studies have seen with in the same cold water pain test for opioids such as oxycodone and morphine. The researchers described the results of the study as “remarkable”, with…
[In the 1950’s and 60’s] psychedelics were of little interest to pharmaceutical companies as the intervention seemed to treat illness, rather than alleviate symptoms. Consequently, the financial imperatives were lacking; fully recovered patients would not require continued medication… Sandoz was reluctant to share such proprietary and patented data (Bonson, 2018). When required by the FDA, the company…
In contrast to the primary hypothesis, psychedelics had no long-lasting effects on the ADE (alcohol deprivation effect) in male and female rats… …when administered in a high dosage regime that is comparable to the one used in clinical studies… Original Article (Nature):Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapseArtwork…
Recent Comments